Current Report Filing (8-k)
22 May 2020 - 10:16PM
Edgar (US Regulatory)
0001270073
false
0001270073
2020-05-21
2020-05-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d) of the
Securities Exchange
Act of 1934
Date of report (Date
of earliest event reported): May 22, 2020
Intercept Pharmaceuticals, Inc.
(Exact Name of Registrant
as Specified in Charter)
Delaware
(State or Other Jurisdiction
of Incorporation)
|
001-35668
(Commission
File Number)
|
22-3868459
(IRS Employer
Identification No.)
|
10 Hudson Yards, 37th Floor
New York, NY 10001
(Address of Principal
Executive Offices and Zip Code)
Registrant’s
telephone number, including area code: (646) 747-1000
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.001
per share
|
|
ICPT
|
|
Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 7.01.
|
Regulation FD Disclosure.
|
On May 22, 2020, Intercept Pharmaceuticals, Inc. issued a press
release announcing a regulatory update with respect to its New Drug Application to the U.S.
Food and Drug Administration for obeticholic acid in liver fibrosis due to NASH.
A copy of such press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein
by reference.
The information in this Item 7.01 and Exhibit 99.1 attached
hereto is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that Section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended,
or the Exchange Act, regardless of any general incorporation language in such filing, except as expressly set forth by specific
reference in such filing.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
INTERCEPT PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Sandip Kapadia
|
|
|
|
Name:
|
Sandip Kapadia
|
|
|
Title:
|
Chief Financial Officer and Treasurer
|
|
|
|
|
|
Date: May 22, 2020
Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart
From Apr 2024 to May 2024
Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart
From May 2023 to May 2024